Anti-c-Mpl antibody-positive acquired amegakaryocytic thrombocytopenia with immune thrombocytopenia-like features in mixed connective tissue disease

Clicks: 17
ID: 330778
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #33 of 59 articles by views in Modern Rheumatology Case Reports

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Acquired amegakaryocytic thrombocytopenia is a rare cause of severe thrombocytopenia characterized by a marked reduction in bone marrow megakaryocytes and may be difficult to distinguish clinically from immune thrombocytopenia. Acquired amegakaryocytic thrombocytopenia has been reported in various autoimmune and non-autoimmune conditions but has not previously been described in a patient with mixed connective tissue disease. We describe the case of a 63-year-old woman with longstanding mixed connective tissue disease who developed severe thrombocytopenia with mucosal bleeding and purpura. Although she was initially treated for presumed immune thrombocytopenia with platelet transfusion, prednisolone, and intravenous immunoglobulin, followed by intravenous methylprednisolone pulse therapy, her platelet count failed to improve. A subsequent bone marrow biopsy revealed relatively preserved erythroid and granulocytic haematopoiesis with a marked reduction in megakaryocytes, and acquired amegakaryocytic thrombocytopenia was diagnosed after myelodysplastic syndrome and leukaemia had been excluded. Treatment with rituximab and eltrombopag resulted in rapid platelet recovery, and remission has been sustained for 14 months, including after two maintenance rituximab doses administered during follow-up. Testing performed during follow-up revealed positivity for an antibody against the thrombopoietin receptor, suggesting a possible immune-mediated mechanism of impaired megakaryopoiesis. The markedly elevated immature platelet fraction and platelet-associated immunoglobulin G also raised the possibility of concomitant immune thrombocytopenia-like peripheral platelet destruction. This case highlights the importance of considering acquired amegakaryocytic thrombocytopenia in patients with systemic autoimmune disease and severe thrombocytopenia refractory to corticosteroids or intravenous immunoglobulin, while recognizing that impaired platelet production and peripheral platelet destruction may overlap.
Reference Key
openalex_W7215048233 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Tatsuya Ueno, Shunjiro Kurihara, Kodai Kato, Shuhei Kameda, Hiroshi Nakajima
Are you one of these authors? Claim your profile
Journal Modern Rheumatology Case Reports
Year 2026
DOI
10.1093/mrcr/rxag093
URL
https://doi.org/10.1093/mrcr/rxag093
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.